CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

BioCardia to Support Development of Potential Cell Therapy Products

BioCardia to Support Development of...

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

BioCardia to Support Development of Potential Cell Therapy Products

BioCardia to Support Development of...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Life Sciences Review Life Sciences Review | Thursday, April 21, 2022
Tweet

Congress established the Breakthrough Therapy designation in July 2012, allowing biotechnology and pharmaceutical companies to accelerate the examination of investigational medications.


FREMONT, CA: Congress established the Breakthrough Therapy designation in July 2012, which allows biotechnology and pharmaceutical companies to accelerate the examination of investigational medications that may have treatment advantages over current therapies for difficult-to-treat diseases. Gazyva, a drug used in conjunction with chlorambucil for patients with chronic lymphocytic leukemia, became the first breakthrough therapy approved by the FDA in November 2013. Numerous medications have received the designation since then, with several achieving commercialization. The rising market of psychedelics, where businesses like Tryp Therapeutics are trying to offer relief for patients with chronic pain by designing evidence-based innovation in areas where today's approved drugs and therapies are ineffective, remains underrepresented on the FDA breakthrough therapy list and could make waves soon. COMPASS Pathways Plc, Mind Medicine Inc., ATAI Life Sciences N.V., and Cybin Inc. are among a small group of impressive organizations that are progressing or have already sophisticated psychedelic treatments into Phase 2 of the FDA clinical trial process.


Opportunity Beyond Mental Illness


Many psychedelics firms are relying on data (historical, contemporary, and anecdotal) that suggests psychedelics can help with mental illnesses and ailments. To mention a few mental illness targets, these indicators include post-traumatic stress disorder ("PTSD"), anxiety, attention deficit-hyperactivity disorder ("ADHD"), and several types of depression. These indications, notably depression, are attracting a lot of attention since they represent numerous people who want more effective medication or therapy with fewer adverse side effects than presently available.


While depression is a hot topic among psychedelic firms, Tryp Therapeutics is confident that psilocybin may be used to address a variety of other unmet needs, including chronic pain and certain eating disorders. As part of Tryp's Psilocybin-for-Neuropsychiatric Disorders, or PFN, program, the San Diego-based business has established an experienced management team and a group of world-class advisers to give their experience in researching new medication candidates for chronic pain and eating disorders. For its Phase 2a clinical studies, Tryp uses its TRP-8802 product, a conventional oral form of synthetic psilocybin, to prove its efficacy throughout many indications.


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/tryp-therapeutics-breaks-new-grounds-in-investigational-drugs-nwid-494.html